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Abstract: A cytotoxic alkaloidal meroterpenoid, saccharoquinoline (1), has been isolated from the
fermentation broth of the marine-derived bacterium Saccharomonospora sp. CNQ-490. The planar
structure of 1 was elucidated by 1D, 2D NMR, and MS spectroscopic data analyzes, while the
relative configuration of 1 was defined through the interpretation of NOE spectroscopic data.
Saccharoquinoline (1) is composed of a drimane-type sesquiterpene unit in combination with an
apparent 6,7,8-trihydroxyquinoline-2-carboxylic acid. This combination of biosynthetic pathways
was observed for the first time in natural microbial products. Saccharoquinoline (1) was found to
have cytotoxicity against the HCT-116 cancer cell line by inducing G1 arrest, which leads to cell
growth inhibition.
Keywords: Saccharomonospora sp.; meroterpenoid; marine natural product; cytotoxicity
1. Introduction
The marine-derived bacterium Saccharomonospora sp. CNQ-490 is an actinomycete which,
based upon phylogenetic analysis, represents a new operational taxonomic unit within the genus
Saccharomonospora [1]. Previous chemical investigations of the strain CNQ-490 led to the isolation
of a series of alkaloids, namely, the lodopyridones [1,2], which revealed a unique combination of
ethanolamine, thiomethyl-substituted 4-pyridone, thiazole, and chloroquinoline moieties within its
structure. A further study of this strain also yielded three new α-pyrones—the saccharomonopyrones
A–C [3]. Further, a recent genomic study on Saccharomonospora sp. CNQ-490 led to the successful
heterologous expression of a silent bio-synthetic gene cluster, which lead to the discovery of the new
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anti-biotic taromycins A and B [4,5]. The observation of 19 apparent biosynthetic gene clusters in this
strain also indicated that this actinomycete could be a promising source for additional structurally
diverse secondary metabolites [4]. LC-MS analysis on a large-scaled culture crude extract of this strain
revealed a peak with UV absorption signals at λmax 281 and 349 nm, which corresponds to a molecular
weight of 425. HPLC-UV-guided purification of the culture extract of the strain yielded an alkaloidal
meroterpenoid saccharoquinoline (1, Figure 1).
Figure 1. Chemical structure of saccharoquinoline (1).
2. Results and Discussion
2.1. Chemical Structure Elucidation
Saccharoquinoline (1) was isolated as a viscous oil by repeated C18 silica flash column fractionation
and final C18 HPLC purifications. The molecular formula of 1 was deduced as C25H31NO5 from the
analysis of HRESIMS data in combination with NMR spectroscopic data. A strong IR absorption
at 1708 cm-1 indicated the presence of carbonyl functionality, which was ultimately assigned as a
carboxylic acid. The 1H-NMR spectrum of 1 exhibited two doublet ortho-aromatic protons (H-7′ (δH
8.40, 1H, J = 8.6 Hz) and H-8′ (δH 7.92, 1H, J = 8.6 Hz)), and four methyl singlets (H-12 (δH 0.85),
H-13 (δH 0.90), H-14 (δH 0.94), and H-15 (δH 1.18)). The 13C NMR and HSQC spectroscopic data also
indicated the presence of four methyl singlets (C-12 (δC 21.5), C-13 (δC 33.2), C-14 (δC 14.6), and C-15
(δC 20.3)), six methylenes (C-1 (δC 38.5), C-2 (δC 18.0), C-3 (δC 41.3), C-6 (δC 19.3), C-7 (δC 40.3), and
C-11 (δC 17.9)), two methines (C-5 (δC 55.3) and C-9 (δC 51.2)), two aromatic methines (C-7′ (δC 132.1)
and C-8′ (δC 116.9)), three un-protonated sp3 (C-4 (δC 32.8), C-8 (δC 78.1), and C-10 (δC 36.6)), and eight
un-protonated sp2 carbons (C-1′ (δC 104.9), C-2′ (δC 122.8), C-3′ (δC 133.6), C-4′ (δC 135.0), C-5′ (δC
136.9), C-6′ (δC 145.8), C-9′ (δC 140.8), and C-10′ (δC 165.6)) (Table 1).
Further interpretation of the 2D spectroscopic data allowed us to assign the structure of 1. First, the
drimane-type sesquiterpene unit was secured from the analysis of the COSY and HMBC spectroscopic
data. COSY correlations (H-1 (δH 0.99, 1.83)/H-2 (δH 1.44, 1.66)/H-3 (δH 1.18, 1.39), H-5 (δH 1.08)/H-6
(δH 1.42, 1.74)/H-7 (δH 1.73, 2.15), and H-9 (δH 1.67)/H-11 (δH 2.69, 2.91)), the HMBC correlations from
gem dimethyls H3-12 and H3-13 to C-3, C-4, and C-5, a methyl singlet H3-14 to C-1, C-5, C-9, and C-10,
and from a methyl singlet H3-15 to C-7, C-8, and C-9 permitted the establishment of a drimane moiety.
Second, the quinoline moiety could also be constructed by the interpretation of the 1D and 2D
NMR spectroscopic data. The COSY spectrum confirmed two ortho-coupled aromatic protons, H-7′
and H-8′. HMBC correlations were observed from H-8′ to C-2′, and from H-7′ to C-1′, C-3′, and C-9′,
and from the exchangeable proton 4′-OH to C-3′, C-4′, and C-5′. These observations, coupled with the
presence of an aromatic nitrogen, suggested the presence of a quinoline moiety. The typical carbon
chemical shifts of C-5′ (δC 136.9) and C-6′ (δC 145.8) indicated the attachment of oxygen atoms to C-5′
and C-6′. HMBC NMR correlations from methylene H2-11 to C-1′ and C-6′ permitted the connectivity
of C-9/C-11/C-1′ and the typical oxygenated carbon chemical shift of C-8 (δC 78.1) indicated the
connectivity of C-8 and C-6′ through an oxygen atom. Even though no relevant HMBC correlations
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were observed for the carboxylic group of C-10′, this moiety was placed at C-9′, which was based
on the observation of ortho-coupled protons for protons H-7′ and H-8′. Quinoline-2-carboxylic acids
are common metabolites and their spectroscopic data are well known. Thus, the planar structure of
saccharoquinoline (1) was determined, as shown in Figure 2A.
The complete relative stereo-structure of 1 was readily derived by the interpretation of NOESY
NMR correlations of the drimane skeleton. NOESY correlations between H-9 and H-11β (δH 2.69), and
H-5 and H-9 indicated that those protons (H-5, H-9, and H-11β) were located on the same side of the
tricyclic ring system (Figure 2B).
Table 1. NMR spectroscopic data for saccharoquinoline (1) in DMSO-d6, δ in ppm a.
1
No.
δC, mult. b δH (J in Hz) COSY HMBC
1 38.5, CH2
0.99, brd; 1.83, d
(14.3) 2
2 18.0, CH2 1.44, m c; 1.66, m c 1, 3
3 41.3, CH2 1.18 c; 1.39 c 2
4 32.8, C
5 55.3, CH 1.08 c 4, 6, 10, 12, 14
6 19.3, CH2 1.42, m c; 1.74, mc 7
7 40.3, CH2
1.73 c; 2.15, dt (12.3,
3.6) 6
8 78.1, C
9 51.2, CH 1.67 c 11 8, 10, 11, 14, 15
10 36.6, C
11 17.9, CH2
2.69, dd (16.8, 5.2);
2.91, dd (16.8, 13.1) 9 8, 9, 1
′, 6′
12 21.5, CH3 0.85, s 3, 4, 5, 13
13 33.2, CH3 0.90, s 3, 4, 5, 12
14 14.6, CH3 0.94, s 1, 5, 9, 10
15 20.3, CH3 1.18, s 7, 8, 9
1′ 104.9, C
2′ 122.8, C
3′ 133.6, C
4′ 135.0, C
5′ 136.9, C
6′ 145.8, C
7′ 132.1, CH 8.40, d (8.6) 8′ 1′, 3′, 9′
8′ 116.9, CH 7.92, d (8.6) 7′ 2′
9′ 140.8, C
10′ 165.6, C
4′-OH 9.54, s 3′, 4′, 5′
a 300 MHz for 1H NMR and 75 MHz for 13C NMR. b Numbers of attached protons were determined by analysis of
2D NMR spectroscopic data (500 MHz). c Overlapping signals.
Saccharoquinoline (1) is an alkaloidal meroterpenoid composed of a common drimane
sesquiterpene and an unreported 6,7,8-trihydroxyquinoline-2-carboxylic acid moiety. Searches of
the Antimarin Database showed 237 secondary metabolites containing the quinoline moiety isolated
from microorganisms, but there were no reports of compounds having a hybrid structure, as in 1.
The closest chemical structure to 1 is that of thallusin (2), which was isolated from the marine bacterium
Flavobacterium sp. in 2005 [6]. Thallusin (2) has a broken ring structure between the C-4′ and C-5′ of
1, with a further oxidation state that has two carboxylic acids. The initial isolation of the thallusin
was followed by several synthetic efforts [7,8]. In 2014, a chiral synthetic route based on enzymatic
hydrolysis was developed to correct the originally proposed stereo-structure [9].
The structural similarity of these two meroterpenoids implies that they share the same biosynthetic
pathway; however, they have an additional oxidative cleavage of the C-4′–C-5′ bond.
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It is not clear how these two metabolites are related. On the basis of feasible chemical conversions,
the vicinal aromatic diol of 1 can be oxidized to the ring open dicarboxylic acid, in a fashion that
is analogous to the oxidation of catechol to muconic acid [10]. Saccharoquinoline (1) and thallusin
(2) show rare quinoline starting at the terpenoid pathway (Figure 3). A quinoline moiety from
lodopyridones, which was isolated from the same strain, also supports this hypothesis [1,2].
Figure 2. (A) COSY and key HMBC correlations. (B) Key NOESY correlations of saccharoquinoloine (1).
Figure 3. Plausible biosynthetic pathway for saccharoquinoline (1) and thallusin (2).
2.2. Bioactivities
Next, we tested saccharoquinoline (1) for its cytotoxic effect in diverse tumor-originating cancer
cell lines such as H1299, A549, HCT116, PC-3, HepG2, and in the BJ normal cell line [11]. At a
concentration of 10 µM, 1 induced cell growth inhibition of approximately 50% in H1299 and HCT116.
The treatment at the highest concentration of 25 µM showed strong inhibition in the H1299, HCT116,
and PC-3 cell lines, but also induced cell mortality of approximately 43% in the BJ cells (Table 2).
Among the tested cancer cell lines, we chose the HCT116 colon cancer cells, which showed a high
cytotoxic response, and confirmed the growth inhibition of 1 by using live cell growth measurements.
As shown in Figure 4, 1 inhibited HCT-116 in a dose-dependent manner. Cell cycle regulation, and
particularly G1 arrest, is one of the origins of cytotoxicity. Therefore, we compared the expressions
of G1 check proteins such as CDKs and cyclins in the 1-treated and control cells. Figure 5 depicts
the strong inhibition of cyclins D1 and D3, which play an important role in the transition from the
G1 phase to the S phase. These data showed that saccharoquinoline (1) induced G1 arrest by the
downregulation of cyclins D1 and D3 in colon cancer cells, resulting in cell growth inhibition [12].
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Table 2. Viability assay in several types of cancer cells and normal cells after treatment with
saccharoquinoline (1) for 72 h.
Cancer Normal
Concentration
(µM)
Lung Colon Prostate Liver Skin
H1299 A549 HCT116 PC-3 HepG2 BJ
DMSO (0.1%) 100 100 100 100 100 100
Doxorubicin 10 6 5 11 24 7 16
1
1 87 103 89 106 98 87
10 45 100 39 88 82 80
25 29 81 25 46 71 57
Figure 4. Colon cancer cell (HCT116) growth in saccharoquinoline (1)-treated and vehicle-treated
(DMSO, 0.1%) cells measured using live cell imaging. Doxorubicin treated cells were used as a control
for cytotoxicity.
Figure 5. Downregulation of cell cycle checkpoint proteins involved in the G1 phase transition to the S
phase. HCT116 cells were treated with 1 (10 µM, +) for 24 hours or 48 hours, and with vehicle (DMSO,
0.1%). The expressions of CDK2, CDK4, CDK6, cyclin D1, and cyclin D3 were illustrated by Western
blot analysis. GAPDH was used as the internal control.
3. Materials and Methods
3.1. General Experimental Procedures
An optical rotation was measured on an Autopol III (Rudolph Research Analytical, Hackettstown,
NJ, USA) polarimeter with a 5-cm cell, and the UV spectra were recorded on a Scinco UVS-2100
spectrophotometer (Sinco, Daejeon, Korea). IR spectra were taken on a Perkin-Elmer 1600 FT-IR
spectrometer (Waltham, MA, USA). NMR spectra were recorded on a Varian Inova NMR spectrometer
(Varian Inc., Palo Alto, CA, USA; 300 and 75 MHz for 1H and 13C NMR, respectively) using the
signals of the residual solvent as internal references; δH 2.50 and δC 39.5 ppm for dimethyl sulfoxide-d6
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(DMSO-d6). 2D NMR spectra were recorded on a Varian Inova 500 MHz NMR spectrometer (Varian
Inc., Palo Alto, CA, USA). High-resolution ESIMS spectra were obtained using a JEOL JMS-AX505WA
mass spectrometer (JEOL Ltd. Tokyo, Japan). Low-resolution LC-MS data were acquired using an
Agilent Technologies 6120 quadrupole LC/MS system (Agilent Technologies, Santa Clara, CA, USA)
with a reversed-phase column (Phenomenex Luna C18 (2) 100 Å, 50 mm × 4.6 mm, 5 µm) at a flow
rate of 1.0 mL/min. Open column chromatography was performed on C18 silica (40–63 µm, ZEO prep
90) with a gradient solvent of water (H2O) and methanol (MeOH).
3.2. Strain Isolation and Fermentation
Strain CNQ-490 was isolated from a sediment sample collected at a depth of 45 m, 2 km west of
the Scripps pier in La Jolla, CA. The 16S rDNA sequence of this strain showed the closest identification
with the genus Saccharomonospora (GenBank accession number EU214929). A 40-L culture of the strain
CNQ-490 was performed at RT using 2.5-L Ultra Yield Flasks (Thomson Scientific, Oceanside, CA,
USA), each containing 1 L of the medium (10 g/L of soluble starch, 2 g/L of yeast, 4 g/L of peptone,
10 g/L of CaCO3, 20 g/L of KBr, 8 g/L of Fe2(SO4)3·4H2O dissolved in 1000 mL of artificial seawater)
at 25 ◦C with shaking at 150 rpm. After 7 days of culture, the whole culture broth was extracted with
ethyl acetate (EtOAc), and the solvent was removed in vacuo to yield 2.2 g of EtOAc extract.
3.3. Extraction and Purification
The organic extract was first fractionated by reversed-phase C18 silica flash chromatography using
step-gradient elution (80% of H2O in MeOH to 100% MeOH, and 500 mL each, but the last solvent,
which was 1000 mL, had two fractions) to yield 10 fractions. Fraction 7, eluted with 80% of MeOH in
water, contained saccharoquinoline (1). This fraction (112 mg) was purified by reversed-phase HPLC
under isocratic conditions with 60% of acetonitrile in H2O to yield 2.5 mg of 1 (monitored with a UV
detector at 281 nm and a retention time of 43.5 minutes).
Saccharoquinoline (1): Yellowish oil, [α]D25 + 55 (c 0.002, MeOH); UV (MeOH) λmax (log ε) 200
(2.15), 281 (2.09), and 349 (1.24) nm; IR (KBr) νmax 3422, 2927, 1708, 1624, and 1452 cm-1; 1H and
13C NMR data, Table 1 and Supplementary Materials; HRESIMS m/z 426.2289 [M + H]+ (calcd for
C25H32NO5, 426.2275).
3.4. Cytotoxicity Test
Cancer cell lines, obtained from ATCC (VA, USA), were cultured in a basal culture media
containing 10% FBS (GE Healthcare Life Sciences, Pittsburgh, PA, USA) and 1% penicillin/streptomycin
(GE Healthcare Life Sciences, Pittsburgh, PA, USA). The basal culture media used was MaCoys’ 5A
(Life Technologies, Carlsbad, MA, USA) for HCT116 (ATCC CCL-247), RPMI (Life Technologies,
Carlsbad, MA, USA) for H1299 (ATCC CRL-5803), and DMEM (Life Technologies, Carlsbad, MA,
USA) for A549 (ATCC CCL-185), PC-3 (ATCC CRL-1435), and HepG2 (ATCC HB-8065). The normal
human fibroblast cell line, BJ (ATCC CRL-2522), was cultured in DMEM supplemented with 10% FBS
and 1% penicillin/streptomycin. For the cytotoxicity test, cells with a total of 2.5 × 103 per well of
the 96 well culture plate were seeded, and on the next day, saccharoquinoline (1) was treated as 1,
10, and 25 µM in a basal media containing 1% FBS with a final concentration of 0.1% DMSO. Three
days (72 h) after treatment, 100 µL Cell Titer Glo reagent (Promega, Madison, WI, USA) was added to
each well and luminescence activity was measured using a multifunctional microplate reader (Tecan,
Männedorf, Switzerland). Cell viability was analyzed as percent (%) viability compared with the
DMSO (0.1%)-treated control. Doxorubicin was used as a positive control. For HCT116 cell growth
analysis in the live state, cells were seeded to be the number of 2.5 × 103 in each well of a 96-well plate,
and cell growth, with or without treatment of 1, was monitored for 4 days. Cell growth was measured
by the percent (%) of cell confluence in each well of a 96-well plate using the IncuCyte ZOOM program
(Sartorius, Göttingen, Germany).
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3.5. Western Blot
Saccharoquinoline (1, 10 µM, with 0.1% DMSO) or vehicle (DMSO, 0.1%) was added to HCT116
cells cultured in a basal culture media supplemented with 1% FBS. Cells were harvested 24 h and
48 h after treatment and were lysed with RIPA (radioimmunoprecipitation assay) buffer (Roche, Basel,
Switzerland) containing protease and phosphatase inhibitors (Roche). Cell lysates were kept on ice
for 30 min and centrifuged at 15,000 rpm for 20 min. Then, supernatants were transferred into new
tubes and the protein concentrations were measured using a BCA protein assay kit (Thermo Fisher
Scientific, Waltham, MA, USA). Next, the protein extracts (30 µg) were electrophoresed and transferred
to a PVDF membrane (EMD Millipore, Burlington, MA, USA). Then, the membrane was incubated
with primary antibodies against CDK2, CDK4, CDK6, cyclin D1, cyclin D3, and GAPDH, purchased
from Cell Signaling Technology (Danvers, MA, USA), at 4 ◦C overnight. The primary antibodies
were detected by incubation with a horseradish peroxidase-conjugated secondary antibody (Bethyl
Laboratories, Montgomery, TX, USA) at 25 ◦C for 1 h. Bindings of antibodies were visualized by an
ImageQuant LAS4000 imager (GE Healthcare Life Sciences) after incubation with an ECL substrate
(Bio-Rad, Hercules, CA, USA).
4. Conclusions
In conclusion, a cytotoxic alkaloidal meroterpenoid, saccharoquinoline (1), was isolated from
Saccharomonospora sp. CNQ-490 as the first candidate for a hybrid structure between a drimane
sesquiterpene and the rare 6,7,8-trihydroxyquinoline-2-carboxylic acid. The successful discovery of 1
along with the diversity of previously reported secondary metabolites from this Saccharomonospora
strain, coupled with the genomic biosynthetic gene cluster information from previous studies,
emphasizes the significant biosynthetic potential of the strain.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/2/98/s1,
Figure S1: 1H NMR spectrum (300 MHz) of saccharoquinoline (1) in DMSO-d6; Figure S2: 13C NMR spectrum
(75 MHz) of saccharoquinoline (1) in DMSO-d6; Figure S3: gCOSY spectrum (500 MHz) of saccharoquinoline
(1) in DMSO-d6; Figure S4: gHSQC spectrum (500 MHz) of saccharoquinoline (1) in DMSO-d6; Figure S5:
gHMBC spectrum (500 MHz) saccharoquinoline (1) in DMSO-d6; Figure S6: gNOESY spectrum (500 MHz) of
saccharoquinoline (1) in DMSO-d6.
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